Glenmark secures USFDA nod for Tadalafil, Gabapentin Enacarbil, Apremilast Tablets

Published On 2020-12-31 09:46 GMT   |   Update On 2023-10-07 11:15 GMT
Advertisement

MumbaiDrug major, Glenmark Pharmaceuticals Limited, today announced that the company has received United States Food & Drug Administration (USFDA) final approval for Tadalafil Tablets, tentative approvals for Gabapentin Enacarbil Extended-Release Tablets and Apremilast Tablets.

Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg and 20 mg is the generic version of Cialis Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg, of Eli Lilly and Company.

Advertisement

According to IQVIA sales data for the 12 month period ending November 2020, the Cialis Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg market achieved annual sales of approximately $125.5 million*.

The company has also received tentative approval by the USFDA for Gabapentin Enacarbil Extended-Release Tablets, 300 mg and 600 mg, the generic version of Horizant Extended-Release Tablets, 300 mg and 600 mg, of Arbor Pharmaceuticals, LLC.

The Horizant market achieved annual sales of approximately $99.5 million.

Additionally, Glenmark has received tentative approval for Apremilast Tablets, 10 mg, 20 mg and 30 mg, the generic version of Otezla Tablets, 10 mg, 20 mg and 30 mg, of Amgen, Inc.

The Otezla Tablets, 10 mg, 20 mg and 30 mg market achieved annual sales of approximately $2.7 billion.

Glenmark's current portfolio consists of 167 products authorized for distribution in the U.S. marketplace and 44 ANDA's pending approval with the U.S. FDA. 

Read also: FIRST: Glenmark launches Remogliflozin, Vildagliptin FDC drug priced at Rs 14 per tablet to treat diabetes in India

Glenmark Pharmaceuticals Ltd. is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology.




Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News